The BRADY UROLOGICAL INSTITUTE in cooperation with Guilford Pharmaceuticals and 10 nationwide medical institutions is participating in a clinical research trial to evaluate the effectiveness of GPI 1485. GPI 1485, an investigational, human-made compound called a neuroimmunophilin, is being studied to see if it can protect penile nerves from damage in patients undergoing radical prostatectomy. In animal studies, this neuroimmunophilin has been shown to both protect penile nerves from damage and regrow damaged penile nerves but this effect has not been studied in humans. This study will be the first to examine the effect of GPI 1485 on the return of erectile function following bilateral nerve sparing prostate cancer surgery.

Principal Investigator: Dr. Arthur Burnett

Protocol: Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 3 Arm, 12-Month Study to Evaluate the Effects of GPI 1485 on Erectile Function in Patients Undergoing Bilateral Nerve-Sparing Radical Retropubic Prostatectomy for Prostate Carcinoma

Contact Person:
Irene Trueheart, R.N.
(443) 287-1011
itruehe1@jhem.jhmi.edu

WIRB 20031872
Script 1086389